Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer

References

• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360 (2004).
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
   PubMed Web of Science ®Google Scholar
• Berzofsky JA. A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. Vaccine 30(29), 4323–4327 (2011).
   PubMedGoogle Scholar
• Berzofsky JA, Terabe M, Wood LV. Strategies to use immune modulators in therapeutic vaccines against cancer. Semin. Oncol. 39(3), 348–357 (2012).
   PubMed Web of Science ®Google Scholar
• Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1(3), 209–219 (2001).
   PubMed Web of Science ®Google Scholar
• Gross DA, Graff-Dubois S, Opolon P et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J. Clin. Invest. 113(3), 425–433 (2004).
   PubMedGoogle Scholar
• Oh S, Perera LP, Burke DS, Waldmann TA, Berzofsky JA. IL-15/IL-15R alpha-mediated avidity maturation of memory CD8+ T cells. Proc. Natl Acad. Sci. USA 101(42), 15154–15159 (2004).
   PubMed Web of Science ®Google Scholar
• Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl Acad. Sci. USA 100(6), 3392–3397 (2003).
   PubMedGoogle Scholar
• Oh S, Perera LP, Terabe M, Ni L, Waldmann TA, Berzofsky JA. IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc. Natl Acad. Sci. USA 105(13), 5201–5206 (2008).
   PubMed Web of Science ®Google Scholar
• Janssen EM, Droin NM, Lemmens EE et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434(7029), 88–93 (2005).
   PubMedGoogle Scholar
• Ahlers JD, Belyakov IM, Terabe M et al. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L. Proc. Natl Acad. Sci. USA 99(20), 13020–13025 (2002).
   PubMedGoogle Scholar
• Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA. Selective induction of high avidity CTL by altering the balance of signals from antigen presenting cells. J. Immunol. 170, 2523–2530 (2003).
   PubMed Web of Science ®Google Scholar
• Zhu Q, Egelston C, Gagnon S et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J. Clin. Invest. 120(2), 607–616 (2010).
   PubMed Web of Science ®Google Scholar
• Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl Acad. Sci. USA 93, 4102–4107 (1996).
   PubMed Web of Science ®Google Scholar
• Swann JB, Coquet JM, Smyth MJ, Godfrey DI. CD1-restricted T cells and tumor immunity. Curr. Top. Microbiol. Immunol. 314, 293–323 (2007).
   PubMedGoogle Scholar
• Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21, 483–513 (2003).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195(5), 617–624 (2002).
   PubMed Web of Science ®Google Scholar
• O'Konek JJ, Illarionov P, Khursigara DS et al. Mouse and human iNKT cell agonist beta-mannosylceramide reveals a distinct mechanism of tumor immunity. J. Clin. Invest. 121, 683–694 (2011).
   PubMedGoogle Scholar
• O'Konek JJ, Kato S, Takao S et al. beta-mannosylceramide activates type I natural killer T cells to induce tumor immunity without inducing long-term functional anergy. Clin. Cancer Res. (2013) ( In Press).
   PubMedGoogle Scholar
• Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 369(2), 122–133 (2013).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9(3), 162–174 (2009).
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 65(24), 11743–11751 (2005).
   PubMed Web of Science ®Google Scholar
• Terabe M, Matsui S, Noben-Trauth N et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1(6), 515–520 (2000).
   PubMed Web of Science ®Google Scholar
• Terabe M, Matsui S, Park J-M et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198(11), 1741–1752 (2003).
   PubMed Web of Science ®Google Scholar
• Terabe M, Swann J, Ambrosino E et al. A nonclassical non-Va14Ja18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202(12), 1627–1633 (2005).
   PubMed Web of Science ®Google Scholar
• Park JM, Terabe M, van den Broeke LT, Donaldson DD, Berzofsky JA. Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int. J. Cancer 114(1), 80–87 (2004).
   Google Scholar
• Ambrosino E, Terabe M, Halder RC et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: A new immunoregulatory axis. J. Immunol. 179, 5126–5136 (2007).
   PubMed Web of Science ®Google Scholar
• Izhak L, Ambrosino E, Kato S et al. Delicate balance among three types of T cells in concurrent regulation of tumor immunity. Cancer Res. 73(5), 1514–1523 (2013).
   PubMedGoogle Scholar
• Terabe M, Ambrosino E, Takaku S et al. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin. Cancer Res. 15(21), 6560–6569 (2009).
   PubMed Web of Science ®Google Scholar
• Takaku S, Terabe M, Ambrosino E et al. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int. J. Cancer 126(7), 1666–1674 (2010).
   PubMedGoogle Scholar
• Morris JC, Shapiro GI, Tan AR et al. Phase I/II Study of GC1008: A human anti-transforming growth factor-beta (TGFb) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J. Clin. Oncol. 26(15S) (2008).
   Google Scholar
• Wolfgang CD, Essand M, Vincent JJ, Lee B, Pastan I. TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. Proc. Natl Acad. Sci. USA 97(17), 9437–9442 (2000).
   PubMedGoogle Scholar
• Oh S, Terabe M, Pendleton CD et al. Human CTL to wild type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res. 64, 2610–2618 (2004).
   PubMedGoogle Scholar